LINE - Lineage, Inc.
NOVI, Mich., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lineage, Inc. (NASDAQ: LINE), announced that it will report its financial results for the third quarter of 2026 on Monday, November 9, 2026, after market close. A conference call to discuss these results has been scheduled for 8:00 a.m. Eastern Time on Tuesday, November 10, 2026.
JACKSONVILLE, Fla. and NOVI, Mich.
Lineage, Inc. (NASDAQ: LINE - Get Free Report) declared a quarterly dividend on Tuesday, September 15th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.5325 per share on Wednesday, October 21st. This represents a $2.13 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date is Wednesday, September
NOVI, Mich., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Lineage, Inc. (NASDAQ: LINE) (“Lineage” or the “Company”), the world's largest global temperature-controlled warehouse REIT, today announced the appointment of Paul Beiboer to its Board of Directors (“Board”). Beiboer's appointment to the Board is effective September 23, 2026, and he will also serve as a member of the Board's Talent and Compensation Committee.
REITs have evolved into a larger, more diversified, and better-capitalized asset class, now less sensitive to Treasury yields than in prior cycles. Modern REITs feature lower leverage (34.4% debt), predominantly fixed-rate, long-maturity debt, and strong liquidity, supporting resilience amid higher rates. Supply constraints and rising replacement costs create durable moats for select REIT sectors, especially those with HALO (Heavy Assets, Low Obsolescence) characteristics.
CLEVELAND, Sept. 17, 2026 /PRNewswire/ -- The Board of Directors of Preformed Line Products (Nasdaq: PLPC) on September 14, 2026, declared a regular quarterly dividend in the amount of $0.21 per share on the Company's common shares, payable October 20, 2026, to shareholders of record at the close of business on October 1, 2026.
NOVI, Mich., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lineage, Inc. (NASDAQ: LINE) (the "Company"), the world's largest global temperature-controlled warehouse REIT, today announced that its Board of Directors has declared a cash dividend of $0.5325 per share for the third quarter of 2026. The dividend will be paid on October 21, 2026, to shareholders of record of the Company's common stock as of the close of business on September 30, 2026.
NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Value Line, Inc., (NASDAQ: VALU) reported financial results for the first fiscal quarter ended July 31, 2026.
Plus, Houthi militants expand control near a strategic Red Sea chokepoint, and the Amazon plane crash is putting a spotlight on freight carrier 21 Air.
The world's largest cold-storage operator claims negligence caused a massive blaze and is seeking over $1 billion in damages.
The purchase signals confidence despite the stock price falling over the past 12 months.
LOS ANGELES, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Lineage, Inc. (NASDAQ: LINE) today filed a civil lawsuit in Los Angeles Superior Court against Altus Power, Inc., a commercial solar operator, and its contractor Pearce Services LLC, a subsidiary of CBRE Group, alleging that their negligence caused the June 17, 2026, fire that destroyed Lineage's 500,000 square-foot cold storage facility in the Boyle Heights neighborhood in Los Angeles.
Lineage (LINE) remains a Buy, with valuation offering a strong margin of safety despite near-term macro headwinds and operational volatility. Q2 results beat expectations; AFFO per share fell 6.2% to $0.76, but guidance was raised to $2.80–$3.05 for full year. LINE's technological and operational advantages drive competitiveness, yet higher leverage (net debt/EBITDA at 6.0x) and industry risks require close monitoring.
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Response Rate Endpoints THOUSAND OAKS, Calif., Sept. 8, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced landmark results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's Imfinzi® (durvalumab) compared to durvalumab alone.
New Program Introduces Flexible Rewards, Status Recognition, Milestone Benefits and More Ways for Guests to Unlock Meaningful Value MIAMI, Sept. 1, 2026 /PRNewswire/ -- Carnival Cruise Line launched Carnival Rewards today, a first-of-its-kind loyalty program in the cruise industry that gives guests more ways to earn rewards, achieve status and be recognized in ways that matter most to them.
BlackRock Inc. bought a new position in shares of Lineage, Inc. (NASDAQ: LINE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,260,370 shares of the company's stock, valued at approximately $227,511,000. BlackRock Inc. owned 2.31% of Lineage as of its most recent
BOCA RATON, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- KARMAN LINE ACQUISITION CORP. (the “Company”), a special purpose acquisition company, today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units are expected to be listed for trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “XTERU” beginning August 18, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and warrants will be listed on Nasdaq under the symbols “XTER” and “XTERW,” respectively. The offering is expected to close on August 19, 2026, subject to customary closing conditions.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
Lineage, Inc. (LINE) Q2 2026 Earnings Call Transcript